Tyrosine receptor kinase B is a drug target in astrocytomas
Conclusions.
Our findings provide evidence that constitutively activated NTRK2 alleles, notably the human tumor-associated QKI-NTRK2 fusion, can cooperate with Ink4a/Arf loss to drive astrocytoma formation. Therefore, we propose NTRK2 as a potential therapeutic target in the subset of astrocytoma patients defined by QKI-NTRK2 fusion.
Source: Neuro-Oncology - Category: Cancer & Oncology Authors: Ni, J., Xie, S., Ramkissoon, S. H., Luu, V., Sun, Y., Bandopadhayay, P., Beroukhim, R., Roberts, T. M., Stiles, C. D., Segal, R. A., Ligon, K. L., Hahn, W. C., Zhao, J. J. Tags: Basic and Translational Investigations Source Type: research
More News: Addiction | Astrocytoma | Bone Graft | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Databases & Libraries | Neurology | Study